6,678 trials
Arthroplasty, Replacement, Knee · Knee Arthroplasty, Total
Primary: Western Ontario McMaster (WOMAC) Osteoarthritis Index Pain — 84.0; 78.3 units on a scale
Mental Health · Geriatrics
Primary: Psychomotor Vigilance Test (PVT) — 302.62; 277.13 milliseconds
Liver Transplantation
Primary: Estimated Glomerular Filtration Rate (GFR) — 73.46; 71.95 mL/min — p=0.097
Type 2 Diabetes Mellitus
Primary: Number of Participants by Their Treatment Preference Using Standardized Questions at the End of Treatment Period — 4; 7; 8; 10 Participants — p=0.0141
Adiposity
Primary: Change in Clinician-Reported Submental Fat Rating Scale — 5; 4; 5; 6 Participants
Nicotine Dependence
Primary: Change in Mu-opioid Receptor Binding Potential (BP) Between Baseline and Post-patch Scans — -2.47; -5.94; 5.60; -1.24 ratio
Kidney Failure, Chronic
Primary: Efficacy of Patiromer in Reducing Serum Potassium — 6.17; 6.6; 5.9; 6.47 mEq/L
Pain · Fever · Hepatotoxicity
Primary: Acetaminophen Plasma Clearance Association With Race/Ethnicity — 5.3; 5.9 mL/min/kg — p=0.52
Diabetes Mellitus, Non-Insulin-Dependent · Hypertensive Disease
Primary: Change in Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitors. — -4.88; -5.45 mm/Hg
Schizophrenia · Psychotic Disorder NOS · Schizoaffective Disorder
Primary: Cortical Thickness — 2.53; 2.54; 2.51; 2.52 mm
Parkinson Disease · Overactive Bladder · Impaired Cognition
Primary: Change in Montreal Cognitive Assessment Total Score — 1.5; 2 units on a scale
Wet Age-Related Macular Degeneration
Primary: Standardized Area Under the Curve (AUC) for VEGF A Levels by SIMOA (Quanterix's Single Molecule Array) Method for the Comparative Phase — 18.78; 33.95 pg/mL — p=<0.0001
Hepatitis C
Primary: Treatment Efficacy — 88; 75 % of participants
Congenital Heart Disease
Primary: Total Units of Intraoperative Allogenic Donor Transfusions (ADT) Administered During Procedure Through ICU Arrival. — 5; 4 ADT units
Pain, Postoperative
Primary: Patient Reported Pain — 4.12; 4.37 score on a scale